Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers.
peripheral T-cell lymphoma; autologous stem-cell transplantation; propensity score matching; complete response; partial response; first line
Abstract :
[en] Background: Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to the rarity and the heterogeneity of PTCL, no consensus has been achieved regarding even the type of first-line treatment. The benefit of autologous stem-cell transplantation (ASCT) is, therefore, still intensely debated.
Patients and methods: In the absence of randomized trials addressing the role of ASCT, we performed a large multicentric retrospective study and used both a multivariate proportional hazard model and a propensity score matching approach to correct for sample selection bias between patients allocated or not to ASCT in intention-to-treat (ITT).
Results: Among 527 patients screened from 14 centers in France, Belgium and Portugal, a final cohort of 269 patients 65 years old with PTCL-not otherwise specified (NOS) (N¼78, 29%), angioimmunoblastic T-cell lymphoma (AITL) (N¼123, 46%) and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-ALCL) (N¼68, 25%) with partial (N¼52,
19%) or complete responses (N¼217, 81%) after induction was identified and information about treatment allocation was carefully collected before therapy initiation from medical records. One hundred and thirty-four patients were allocated to ASCT in ITT and 135 were not. Neither the Cox multivariate model (HR¼1.02; 95% CI: 0.69–1.50 for PFS and HR¼1.08; 95% CI: 0.68–
1.69 for OS) nor the propensity score analysis after stringent matching for potential confounding factors (logrank P¼0.90 and 0.66 for PFS and OS, respectively) found a survival advantage in favor of ASCT as a consolidation procedure for patients in response after induction. Subgroup analyses did not reveal any further difference for patients according to response status, stage disease or risk category.
Conclusions: The present data do not support the use of ASCT for up-front consolidation for all patients with PTCL-NOS, AITL, or ALK-ALCL with partial or complete response after induction.
Disciplines :
Hematology
Author, co-author :
Fossard, Gaëlle; Centre de recherche en cancérologie de Lyon
Broussais, Florence; Centre de recherche en cancérologie de Lyon
Coelho, Inês; Portuguese Institute of Oncology
Bailly, Sébastien; CHU de Clermont-Ferrand
Nicolas-Virelizier, Emmanuelle; Centre Leon Berard (Lyon)
Toussaint, Elise; CHU de Strasbourg
Lancesseur, Charles; CHU de Caen
Le Bras, Fabien; CHU Henri Mondor
WILLEMS, Evelyne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers.
Swerdlow S, Campo E, Harris N. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2008.
Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375-2390.
Federico M, Rudiger T, Bellei M et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31: 240-246.
Vose J, Armitage J, Weisenburger D, International T-cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 2017; 129(9): 1095-1102.
de Leval L, Parrens M, Le Bras F et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica 2015; 100(9): e361-e364.
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood 2014; 123(17): 2636-2644.
Simon A, Peoch M, Casassus P et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMSLTP95. Br J Haematol 2010; 151(2): 159-166.
Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124(10): 1570-1577.
Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116(18): 3418-3425.
Abouyabis AN, Shenoy PJ, Sinha R et al. A systematic review and metaanalysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924.
Perrone G, Giulia P, Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol 2014; 51(1): 59-66.
Jethwa KD, Bishton MJ, Fox CP. The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naive patients with peripheral T-cell lymphoma: a systematic review of the literature. Br J Haematol 2016.
Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol 2017; 176(6): 851-866.
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53(282): 457-481.
Cox DR. Regression models and life tables. J Royal Stat Soc Series B 1972; 34: 187-220.
d'Amore F, Gaulard P, Trumper L et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2015; 26(Suppl 5): v108-v115.
Kharfan-Dabaja MA, Kumar A, Ayala E et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017; 23(11):1826-1838.
Cederleuf H, Hjort Jakobsen L, Ellin F et al. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish populationbased study. Leuk Lymphoma 2017; 58(12): 2815-2823.
Abramson JS, Feldman T, Kroll-Desrosiers AR et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014; 25(11): 2211-2217.
Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19(5): 958-963.
Yam C, Landsburg DJ, Nead KT et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol 2016; 91(7): 672-676.
Wilhelm M, Smetak M, Reimer P et al. First-line therapy of peripheral Tcell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 2016; 6(7): e452.
Kitahara H, Maruyama D, Maeshima AM et al. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Ann Hematol 2017; 96(3): 411-420.
Burudpakdee C, Lin HM, Wang W et al. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. J Med Econ 2016; 19(10): 965-972.
